C3.ai Inc vs Regeneron Pharmaceuticals Inc — how do they compare? C3.ai Inc trades at $10.6 (market cap $1.59B), while Regeneron Pharmaceuticals Inc trades at $793.6 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 52.3× C3.ai Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| AI | REGN | |
|---|---|---|
Market Cap | $1.59B | $83.19B |
Sector | Technology | Health |
52-Week High | $19.66 | $812.27 |
52-Week Low | $7.76 | $545.94 |
Enterprise Value | $1.02B | $77.90B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.22, up 3.65% with a bullish technical signal. The company shows revenue growth to $389M in 2025 but continues significant losses with a -187.95% net income margin. Recent recognition as a leader in AI platforms by Forrester Research (August 10, 2026) provides positive momentum, though cash flow remains negative. Analyst consensus is mixed with 21% buy ratings and a $10.20 price target slightly below current levels.
The outlook remains challenging with persistent losses offset by strong market positioning in enterprise AI. Investment opportunity lies in the company's leadership recognition and sector growth potential, while risks include unsustainable cash burn and competitive pressures. The stock faces near-term resistance at $11 with support at $10.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →